Skip to main content

Werewolf Therapeutics, Inc.

HOWL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001785530

In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Werewolf Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of HOWL: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders4439−5
Shares21.0M20.9M−65.1K (−0.3%)
Value$94.5M$42.8M−$51.6M (−54.7%)

New holders (8)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to HOWL in Q4 2022
InstitutionSharesValue% of portfolio
Tejara Capital Ltd128,800$264.0K0.15%
Jacobs Levy Equity Management, Inc101,221$207.5K0.00%
Acadian Asset Management LLC29,501$60.0K0.00%
Two Sigma Investments, LP27,185$55.7K0.00%
Jane Street Group, LLC22,064$45.2K0.00%
Prudential Financial Inc21,000$43.0K0.00%
Chicago Partners Investment Group LLC10,729$41.2K0.00%
Citadel Advisors LLC11,030$22.6K0.00%

Sold out (13)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.